Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has provided an announcement.
Shandong Xinhua Pharmaceutical Company Limited has received a Drug Registration Certificate for its empagliflozin tablets (10 mg) from the National Medical Products Administration. This approval marks a significant step for the company in enhancing its market presence in the pharmaceutical sector, allowing it to proceed with the production and sale of this prescription drug in accordance with pharmaceutical quality management standards.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a pharmaceutical company based in the People’s Republic of China. It operates within the pharmaceutical industry, focusing on the production of prescription drugs. The company is engaged in the domestic production and marketing of various pharmaceutical products, including chemical drug formulations.
YTD Price Performance: -3.27%
Average Trading Volume: 3,104,833
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$9.12B
See more insights into 0719 stock on TipRanks’ Stock Analysis page.
